A detailed history of Pro Share Advisors LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Pro Share Advisors LLC holds 15,218 shares of BPMC stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,218
Previous 13,950 9.09%
Holding current value
$1.78 Million
Previous $1.29 Million 12.21%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$73.17 - $99.79 $92,779 - $126,533
1,268 Added 9.09%
15,218 $1.44 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $91,656 - $193,571
2,085 Added 17.57%
13,950 $1.29 Million
Q3 2023

Nov 13, 2023

BUY
$46.9 - $66.0 $2,063 - $2,904
44 Added 0.37%
11,865 $595,000
Q2 2023

Aug 10, 2023

BUY
$42.2 - $66.37 $26,543 - $41,746
629 Added 5.62%
11,821 $747,000
Q1 2023

May 11, 2023

SELL
$37.97 - $50.0 $89,305 - $117,600
-2,352 Reduced 17.37%
11,192 $503,000
Q4 2022

Feb 02, 2023

BUY
$41.06 - $66.48 $40,649 - $65,815
990 Added 7.89%
13,544 $593,000
Q3 2022

Nov 04, 2022

BUY
$49.93 - $77.7 $11,184 - $17,404
224 Added 1.82%
12,554 $828,000
Q2 2022

Aug 01, 2022

SELL
$45.23 - $70.15 $276,898 - $429,458
-6,122 Reduced 33.18%
12,330 $622,000
Q1 2022

May 10, 2022

SELL
$54.1 - $110.08 $221,214 - $450,117
-4,089 Reduced 18.14%
18,452 $1.18 Million
Q4 2021

Feb 08, 2022

BUY
$94.25 - $115.99 $107,727 - $132,576
1,143 Added 5.34%
22,541 $2.42 Million
Q3 2021

Nov 12, 2021

SELL
$80.98 - $109.47 $516,166 - $697,761
-6,374 Reduced 22.95%
21,398 $2.2 Million
Q2 2021

Aug 13, 2021

BUY
$82.78 - $101.0 $321,434 - $392,183
3,883 Added 16.25%
27,772 $2.44 Million
Q1 2021

May 14, 2021

BUY
$90.71 - $108.28 $183,959 - $219,591
2,028 Added 9.28%
23,889 $2.32 Million
Q4 2020

Feb 09, 2021

BUY
$92.08 - $124.48 $480,289 - $649,287
5,216 Added 31.34%
21,861 $2.45 Million
Q3 2020

Nov 13, 2020

SELL
$66.45 - $92.7 $17,476 - $24,380
-263 Reduced 1.56%
16,645 $1.54 Million
Q2 2020

Aug 03, 2020

BUY
$57.09 - $79.27 $349,676 - $485,528
6,125 Added 56.8%
16,908 $1.32 Million
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $368,233 - $629,311
-7,654 Reduced 41.51%
10,783 $631,000
Q4 2019

Feb 12, 2020

SELL
$66.73 - $82.59 $105,233 - $130,244
-1,577 Reduced 7.88%
18,437 $1.48 Million
Q3 2019

Nov 12, 2019

BUY
$72.9 - $101.41 $70,931 - $98,671
973 Added 5.11%
20,014 $1.47 Million
Q2 2019

Aug 13, 2019

SELL
$73.54 - $97.8 $32,063 - $42,640
-436 Reduced 2.24%
19,041 $1.8 Million
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $11,006 - $19,571
226 Added 1.17%
19,477 $1.56 Million
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $168,791 - $275,059
-3,704 Reduced 16.14%
19,251 $1.04 Million
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $53,961 - $71,741
-916 Reduced 3.84%
22,955 $1.79 Million
Q2 2018

Aug 13, 2018

SELL
$60.96 - $101.18 $108,021 - $179,290
-1,772 Reduced 6.91%
23,871 $1.52 Million
Q1 2018

May 14, 2018

SELL
$73.28 - $102.95 $131,317 - $184,486
-1,792 Reduced 6.53%
25,643 $2.35 Million
Q4 2017

Feb 14, 2018

BUY
$62.91 - $88.32 $171,807 - $241,201
2,731 Added 11.05%
27,435 $2.07 Million
Q3 2017

Nov 13, 2017

BUY
$42.37 - $69.67 $52,708 - $86,669
1,244 Added 5.3%
24,704 $1.72 Million
Q2 2017

Aug 11, 2017

BUY
N/A
23,460
23,460 $1.19 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.98B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.